
Martin Metzenmacher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/189249/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. Clinical Lung Cancer, 2018, 19, e441-e463.	1.1	61
2	Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT?. European Radiology, 2017, 27, 681-688.	2.3	49
3	Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer. Oncogene, 2019, 38, 2953-2966.	2.6	38
4	Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. European Journal of Cancer, 2020, 140, 76-85.	1.3	30
5	Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages. Interactive Cardiovascular and Thoracic Surgery, 2017, 24, ivw392.	0.5	29
6	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. Cancers, 2020, 12, 353.	1.7	24
7	Phosphorylation of p70 Ribosomal Protein S6 Kinase β-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e331-e352.	1.0	13
8	Platelet number and graft function predict intensive care survival in allogeneic stem cell transplantation patients. Annals of Hematology, 2019, 98, 491-500.	0.8	11
9	Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. Journal of Nuclear Medicine, 2021, 62, 191-194.	2.8	10
10	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. European Journal of Cancer, 2021, 149, 211-221.	1.3	9
11	ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. Lung Cancer, 2020, 149, 10-16.	0.9	7
12	Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer. Translational Oncology, 2022, 15, 101279.	1.7	7
13	Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. Future Oncology, 2021, 17, 3965-3976.	1.1	6
14	Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition. Radiation Oncology, 2021, 16, 176.	1.2	6
15	Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications. Lung Cancer, 2022, 168, 10-20.	0.9	6
16	Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy. Journal of Nuclear Medicine, 2021, 62, 1684-1691.	2.8	5
17	A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. Seminars in Nuclear Medicine, 2022, 52, 816-823.	2.5	5
18	Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. Lung Cancer, 2020, 139, 165-168.	0.9	4

#	Article	IF	CITATIONS
19	Acquired Resistance to BRAF/MEK Inhibitor Therapy in BRAF-V600-mutated Squamous Cell Lung Cancer: Concurrent Evolvement of PTEN and MEK1 Mutations. Clinical Lung Cancer, 2021, 22, e668-e672.	1.1	4
20	The clinical utility of <scp>cfRNA</scp> for disease detection and surveillance: A proof of concept study in nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 2180-2191.	0.8	4
21	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial Journal of Clinical Oncology, 2020, 38, 11536-11536.	0.8	3
22	Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer. Journal of Thoracic Disease, 2016, 8, E1254-E1256.	0.6	0